

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: CAMPBELL, et al

International Appln. Serial No.: PCT/EP99/08186

Group Art Unit:

International Appln. Filed: November 1, 1999

Examiner:

For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97


[]	Copies of the references are enclosed
[]	Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d))
[X	A copy of the International Search Report, which issued on International Application No.
	PCT/EP99/08186 is submitted herewith. All of the publications cited in the
	International Search Report are listed on the attached form PTO-1449 and Applicants understand that
	copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- B. [] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
 - (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,

whichever occurs first.

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of this statement.
- [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).
- C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):



Copy

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Lorie Ann Morgan

Registration No. 38,181

GlaxoSmithKline

Five Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

FORM PTO		DISCLOSURE ST	ATEMENT		ATTORNEY DOCKET NO. PG3602USW		SERIAL NO.(Intern'l) PCT/EP99/08186	
					APPLICANT: CAMPBELL, et al			
					FILING (Intern'I) GROUP November 1, 1999			
ř.			U.S. I	ATENT D	OCUMENTS			
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate
~								
			 					
			<u> </u>				<u> </u>	ļ
							 	_
	<u> </u>	<u> </u>		ontinue on p	1906		<u> </u>	<u> </u>
····					DOCUMENTS			<u></u>
	I	Document	Publication	1	100001111111		1	Translation
		Number	Date		Country	Class	Subclass	Yes No
	BA	WO99 12930 A	18 MAR 1999	PCT				
	BB	WO96 06840 A	07 MAR 1996	PCT				
	BC	WO96 31509 A	10 OCT 1996	PCT				<u> </u>
	BD	WO96 21667 A	18 JUL 1996	PCT				<u> </u>
								
		 						
	 					- 		
	 							
							l ————	
			C	ontinue on p	age			
					Title, Journal-Dat			
	CA		", BIOORGANI		d Evaluation of 5,6 CINAL CHEMISTR			
	СВ	ROY, P., et al: "A	New Series of		X-2 Inhibitors: 5,6 Y LETTERS, GB, (
	CC	TALLEY, J. J.: "Selective Inhibitors of Cyclooxygenase-2", EXPERT OPINION ON THERAPEUTIC						
		PATENTS, GB, ASHLEY PUBLICATIONS, vol. 7, no. 1, 1 January 1997, pp. 55-62						
	CD	CARTER, J. S.: "Recently Reported Inhibitors of Cyclooxygenase-2", EXPERT OPINION ON THERAPEUTIC PATENTS, GB, ASHLEY PUBLICATIONS, vol. 8, no. 1, 1 January 1998, pp.21-29						
							 -	:
		<u> </u>						
								
			С	ontinue on p	age			
EXAMINER						I DATE CO	NSIDERED	